Function of GCN5 in the TGF‑β1‑induced epithelial‑to‑mesenchymal transition in breast cancer

Zhao,Liming; Pang,Aixia; Li,Yunchun

doi:10.3892/ol.2018.9134

Function of GCN5 in the TGF‑β1‑induced epithelial‑to‑mesenchymal transition in breast cancer

Authors:
- Liming Zhao
- Aixia Pang
- Yunchun Li
View Affiliations

Affiliations: Department of Nuclear Medicine, Linyi People's Hospital, Linyi, Shandong 276000, P.R. China, Department of Urology, Linyi People's Hospital, Linyi, Shandong 276000, P.R. China, Department of Laboratory Medicine of Jinshan Hospital of Fudan University, Shanghai 201508, P.R. China
Published online on: July 11, 2018 https://doi.org/10.3892/ol.2018.9134
Pages: 3955-3963

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Histone acetyltransferase GCN5 is a critical component of the TGF‑β/Smad signaling pathway in breast cancer cells; however, it remains unknown whether it is involved in the development and progression of breast cancer. The present study investigated the role of GCN5 in the induction of the EMT by TGF‑β1 in breast cancer cells and its underlying molecular mechanism of action. GCN5 activity was elevated and GCN5 mRNA expression and protein expression were increased in MDA‑MB231 cells following stimulation with TGF‑β1. Furthermore, TGF‑β1 stimulation decreased expression of the epithelial cell marker E‑cadherin and increased expression of the mesenchymal cell markers, N‑cadherin and vimentin, as well as the expression of other EMT markers, including snail and slug. However, these changes were reversed following GCN5 knockdown leading to the downregulation of GCN5 expression. GCN5 knockdown also inhibited the viability, migration and invasion of MDA‑MB231 cells, decreased the expression of p‑STAT3, p‑AKT, MMP9 and E2F1, and increased the expression of p21 in MDA‑MB231 cells compared with cells stimulated with TGF‑β1 alone. Therefore, GCN5 may work downstream of TGF‑β/Smad signaling pathway to regulate the EMT in breast cancer.

View Figures

View References

1	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
2	Naume B, Synnestvedt M, Falk RS, Wiedswang G, Weyde K, Risberg T, Kersten C, Mjaaland I, Vindi L, Sommer HH, et al: Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer. J Clin Oncol. 32:3848–3857. 2014. View Article : Google Scholar : PubMed/NCBI
3	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
4	Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
5	Tian M, Neil JR and Schiemann WP: Transforming growth factor-β and the hallmarks of cancer. Cell Signal. 23:951–962. 2011. View Article : Google Scholar : PubMed/NCBI
6	Kahata K, Hayashi M, Asaka M, Hellman U, Kitagawa H, Yanagisawa J, Kato S, Imamura T and Miyazono K: Regulation of transforming growth factor-beta and bone morphogenetic protein signalling by transcriptional coactivator GCN5. Genes Cells. 9:143–151. 2004. View Article : Google Scholar : PubMed/NCBI
7	Jin Q, Yu LR, Wang L, Zhang Z, Kasper LH, Lee JE, Wang C, Brindle PK, Dent SY and Ge K: Distinct roles of GCN5/PCAF-mediated H3K9ac and CBP/p300-mediated H3K18/27ac in nuclear receptor transactivation. EMBO J. 30:249–262. 2011. View Article : Google Scholar : PubMed/NCBI
8	Li S and Shogren-Knaak MA: The Gcn5 bromodomain of the SAGA complex facilitates cooperative and cross-tail acetylation of nucleosomes. J Biol Chem. 284:9411–9417. 2009. View Article : Google Scholar : PubMed/NCBI
9	Chen L, Wei T, Si X, Wang Q, Li Y, Leng Y, Deng A, Chen J, Wang G, Zhu S and Kang J: Lysine acetyltransferase GCN5 potentiates the growth of non-small cell lung cancer via promotion of E2F1, cyclin D1, and cyclin E1 expression. J Biol Chem. 288:14510–14521. 2013. View Article : Google Scholar : PubMed/NCBI
10	Germaniuk-Kurowska A, Nag A, Zhao X, Dimri M, Band H and Band V: Ada3 requirement for HAT recruitment to estrogen receptors and estrogen-dependent breast cancer cell proliferation. Cancer Res. 67:11789–11797. 2007. View Article : Google Scholar : PubMed/NCBI
11	Zhang J, Chen YL, Ji G, Fang W, Gao Z, Liu Y, Wang J, Ding X and Gao F: Sorafenib inhibits epithelial-mesenchymal transition through an epigenetic-based mechanism in human lung epithelial cells. PLoS One. 8:e649542013. View Article : Google Scholar : PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Lo WS, Trievel RC, Rojas JR, Duggan L, Hsu JY, Allis CD, Marmorstein R and Berger SL: Phosphorylation of serine 10 in histone H3 is functionally linked in vitro and in vivo to Gcn5-mediated acetylation at lysine 14. Mol Cell. 5:917–926. 2000. View Article : Google Scholar : PubMed/NCBI
14	Ko H, Jeon H, Lee D, Choi HK, Kang KS and Choi KC: Sanguiin H6 suppresses TGF-β induction of the epithelial-mesenchymal transition and inhibits migration and invasion in A549 lung cancer. Bioorg Med Chem Lett. 25:5508–5513. 2015. View Article : Google Scholar : PubMed/NCBI
15	Chen YL, Lv J, Ye XL, Sun MY, Xu Q, Liu CH, Min LH, Li HP, Liu P and Ding X: Sorafenib inhibits transforming growth factor β1-mediated epithelial-mesenchymal transition and apoptosis in mouse hepatocytes. Hepatology. 53:1708–1718. 2011. View Article : Google Scholar : PubMed/NCBI
16	Liu K, Zhang Q, Lan H, Wang L, Mou P, Shao W, Liu D, Yang W, Lin Z, Lin Q and Ji T: GCN5 potentiates glioma proliferation and invasion via STAT3 and AKT signaling pathways. Int J Mol Sci. 16:21897–21910. 2015. View Article : Google Scholar : PubMed/NCBI
17	Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV and Mann M: Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 325:834–840. 2009. View Article : Google Scholar : PubMed/NCBI
18	Peserico A and Simone C: Physical and functional HAT/HDAC interplay regulates protein acetylation balance. J Biomed Biotechnol. 2011:3718322011. View Article : Google Scholar : PubMed/NCBI
19	Schmierer B and Hill CS: TGFbeta-SMAD signal transduction: Molecular specificity and functional flexibility. Nat Rev Mol Cell Biol. 8:970–982. 2007. View Article : Google Scholar : PubMed/NCBI
20	Chen ZY, Wang PW, Shieh DB, Chiu KY and Liou YM: Involvement of gelsolin in TGF-beta 1 induced epithelial to mesenchymal transition in breast cancer cells. J Biomed Sci. 22:902015. View Article : Google Scholar : PubMed/NCBI
21	Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, et al: Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 21:2000–2008. 2002. View Article : Google Scholar : PubMed/NCBI
22	Xie Y, Naizabekov S, Chen Z and Tokay T: Power of PTEN/AKT: Molecular switch between tumor suppressors and oncogenes. Oncol Lett. 12:375–378. 2016. View Article : Google Scholar : PubMed/NCBI
23	Guo R, Chen J, Mitchell DL and Johnson DG: GCN5 and E2F1 stimulate nucleotide excision repair by promoting H3K9 acetylation at sites of damage. Nucleic Acids Res. 39:1390–1397. 2011. View Article : Google Scholar : PubMed/NCBI